Harrow, Inc. (HROW)
NASDAQ: HROW · Real-Time Price · USD
34.38
-1.24 (-3.50%)
At close: Jul 15, 2025, 4:00 PM
34.37
-0.01 (-0.01%)
After-hours: Jul 15, 2025, 4:20 PM EDT
Harrow Revenue
Harrow had revenue of $47.83M in the quarter ending March 31, 2025, with 38.29% growth. This brings the company's revenue in the last twelve months to $212.86M, up 53.49% year-over-year. In the year 2024, Harrow had annual revenue of $199.61M with 53.32% growth.
Revenue (ttm)
$212.86M
Revenue Growth
+53.49%
P/S Ratio
5.77
Revenue / Employee
$557,220
Employees
382
Market Cap
1.26B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 199.61M | 69.42M | 53.32% |
| Dec 31, 2023 | 130.19M | 41.60M | 46.95% |
| Dec 31, 2022 | 88.60M | 16.12M | 22.24% |
| Dec 31, 2021 | 72.48M | 23.61M | 48.30% |
| Dec 31, 2020 | 48.87M | -2.29M | -4.48% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
HROW News
- 7 hours ago - HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm - PRNewsWire
- 4 days ago - Harrow's Internal $100 Price Target Is Ambitious, But New Bloomberg Data Backs It Up - Seeking Alpha
- 6 days ago - Harrow: Immense Upside Potential - Seeking Alpha
- 8 days ago - HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
- 27 days ago - Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications - Business Wire
- 4 weeks ago - I Am Swimming In Dividends With +7% Yields - Seeking Alpha
- 5 weeks ago - Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals - Business Wire
- 6 weeks ago - Harrow: Epic Growth & Operating Leverage On Full Display - Seeking Alpha